Zobrazeno 1 - 10
of 28
pro vyhledávání: '"35"'
Publikováno v:
Journal of Urology. 197:61-66
We compared clinical characteristics and cancer specific mortality in men diagnosed with prostate cancer before vs after age 50 years.A total of 919 men 35 to 49 years old and 45,098 men 50 to 66 years old who were diagnosed with prostate cancer betw
Autor:
Seung Bae Lee, Zhaoyong Feng, Bruce J. Trock, Heather J. Chalfin, Elizabeth B. Humphreys, Misop Han, Stephen J. Freedland, Hamid Alai, Alan W. Partin, Patrick Walsh, Byong Chang Jeong
Publikováno v:
Journal of Urology. 192:1100-1104
Obesity is a modifiable risk factor associated with worse outcomes for many cancers, yet implications for prostate cancer are not well understood. Notably the impact of body mass index on long-term survival after treatment is unclear. We performed a
Autor:
Judd W. Moul, Valdmir Mouraviev, Cary N. Robertson, David M. Albala, Danielle A. Stackhouse, Matthew A. Uhlman, Leon Sun, Thomas J. Polascik
Publikováno v:
Journal of Urology. 183:997-1002
We determined the predictive power of tumor percent involvement on prostate specific antigen recurrence in patients when stratified by prostate weight.Data on 3,057 patients who underwent radical prostatectomy between 1988 and 2008 was retrieved from
Autor:
Kevin C. Zorn, Mark H. Katz, Scott E. Eggener, Arieh L. Shalhav, Sergey Shikanov, Ofer N. Gofrit, Alan Thong, Gregory P. Zagaja
Publikováno v:
Journal of Urology. 180:2436-2440
Patients with Gleason score 6 microfocal prostate cancer, defined as 5% or less in 1 biopsy core, are often considered to have favorable disease. Few studies have addressed clinical parameters that predict pathological upgrading or up staging at radi
Autor:
Edward F. Chang, Shyam Natarajan, Jiaoti Huang, Leonard S. Marks, Daniel Margolis, Patricia Lieu, Nima Nassiri, Frederick J. Dorey, Alan Priester, Robert E. Reiter
Publikováno v:
The Journal of urology, vol 199, iss 2
PurposeWe assessed focal therapy eligibility in men who underwent multiparametric magnetic resonance imaging and targeted biopsy with correlation to whole mount histology after radical prostatectomy.Materials and methodsSubjects were selected from am
Autor:
James D. Brooks, Ian M. Thompson, Peter S. Nelson, Daniel W. Lin, William J. Ellis, Martin E. Gleave, Yingye Zheng, Peter R. Carroll, Lisa F. Newcomb, Andrew A. Wagner, Raymond S. Lance, Liam C. Macleod, John T. Wei
Publikováno v:
Journal of Urology. 197:1026-1033
During active surveillance for localized prostate cancer, the timing of the first surveillance biopsy varies. We analyzed the Canary PASS (Prostate Cancer Active Surveillance Study) to determine biopsy timing influence on rates of prostate cancer adv
Autor:
Sheldon J. Freedman, Kyle O. Rove, Krystyna Drewnowska, Edouard J. Trabulsi, Junqi Qian, Mark L. Bilowus, W. Lloyd Glover, David G. Bostwick, Thomas K. Huisman, Jed Kaminetsky, E. David Crawford
Publikováno v:
Journal of Urology. 188:1726-1731
The detection of prostate cancer relies primarily on abnormal digital rectal examination or increased serum prostate specific antigen concentration. However, low positive predictive values result in many men with increased prostate specific antigen a
Autor:
Christian von Bodman, Peter T. Scardino, Daher C. Chade, Guilherme Godoy, James A. Eastham, Vincent P. Laudone, Samson W. Fine, Ozdal Dillioglugil
Publikováno v:
Journal of Urology. 187:2082-2086
We determined the frequency and distribution of metastases to pelvic lymph nodes in a contemporary American radical prostatectomy series.In 642 consecutive patients with clinically localized prostate cancer treated by a single surgeon between 2002 an
Publikováno v:
Journal of Urology. 187:1561-1565
Visible hematuria has a cancer yield of up to 24.2%. A large proportion of cases will have no etiology. In this study we determined the incidence of pathology (benign and malignant) in patients with visible hematuria and those with persistent and rec
Publikováno v:
Journal of Urology. 187:868-871
Urogenital cancer is a major health problem in the United States. We assessed potential years of life lost secondary to genitourinary cancer in the United States from 1972 to 2006 using the SEER (Surveillance, Epidemiology and End Results) database.